1. DATE ISSUED MN	I/DD/YYYY 1a. SUPER	1a. SUPERSEDES AWARD NOTICE dated							
06/01/2020 except that any additions or restrictions previously imposed remain in effect unless specifically rescinded									
2. CFDA NO. 93.070 - Environmen	tal Public Health and Eme	gency Response							
3. ASSISTANCE TYPE	3. ASSISTANCE TYPE Cooperative Agreement								
4. GRANT NO. 5 NUE1	EH001393-02-00	5. TYPE OF AWARD							
Formerly		Other							
4a. FAIN NUE1EH001	393	5a. ACTION TYPE	Non-Competing Continuation						
6. PROJECT PERIOD	MM/DD/YYYY		MM/DD/YYYY						
From	09/01/2019	Through	08/31/2024						
7. BUDGET PERIOD	MM/DD/YYYY		MM/DD/YYYY						
From	09/01/2020	Through	08/31/2021						

DEPARTMENT OF HEALTH AND HUMAN SERVICES Centers for Disease Control and Prevention

2939 Brandywine Road Atlanta, GA 30341

NOTICE OF AWARD

AUTHORIZATION (Legislation/Regulations)
Section 317 (k)(2) and 317I of the Public Health Service Act, [42 U.S.C. Sections 247b and 247b-10I, as amended

8. TITLE OF PROJECT (OR PROGRAM)

A Comprehensive Public Health Approach to Asthma Control Through Evidence-Based Interventions

9a. GR	ANTEE NAME AND ADDRESS		9b GRAN	TEE PROJECT DIRECTOR				
HEALTH AND SENIOR SERVICES, MISSOURI DEPARTMENT OF				Mr. Steve Cramer				
	20 WILDWOOD DR	930 Wildwood Dr						
JEFFERSON CITY, MO 65109-5796				son City, MO 65109-5796				
0E11 E10014 0111, WO 03103-3730				e: 573-522-2806				
			0. 0 022 2000					
10a. G	RANTEE AUTHORIZING OFFICIAL		10b. FEDE	RAL PROJECT OFFICER				
M	s. Marcia A Mahaney		Danie	I Burrows				
92	20 Wildwood Drive		Cente	rs for Disease Control and Preventio	า			
Je	efferson City, MO 65109-5796		CDC/	CCHIP/ NCEH/DEHHE/APRHB				
Ph	none: 573-751-6014			blee, GA 30341				
			Phone	e: 770.488.3722				
		ALL AMOUNTS ARE						
	ROVED BUDGET (Excludes Direct Assistance)			COMPUTATION				
I Finar	ncial Assistance from the Federal Awarding Agency Or	nly 	a. Amount	a. Amount of Federal Financial Assistance (from item 11m) 62			625,000.00	
II Total	project costs including grant funds and all other finance	cial participation	b. Less Un	obligated Balance From Prior Budget	Periods		0.00	
a. Salaries and WageS 75,056.00			c. Less Cumulative Prior Award(s) This Budget Period			0.00		
b.	Fringe Benefits	36,027.00	d. AMOUNT OF FINANCIAL ASSISTANCE THIS ACTION			625,000.00		
D.	90 50.10.100	,	13. Total Federal Funds Awarded to Date for Project Period 1,250,			1,250,000.00		
c.	Total Personnel Costs	111,083.00	14. RECOMMENDED FUTURE SUPPORT (Subject to the availability of funds and satisfactory progress of the project):					
d.	Equipment	0.00	(Subject to	rie avaliability of furios and Satisfacto	ry progress or the	ргојест).		
e.	Supplies	217.00	YEAR	TOTAL DIRECT COSTS	YEAR	TOTAL	DIRECT COSTS	
f	Travel	3.109.00	a. 3		d. 6			
	ilavei		b. 4		e. 7			
g.	Construction	0.00	c. 5		f. 8			
h.	Other	3,297.00	15. PROGRAM ALTERNATIVE	INCOME SHALL BE USED IN ACCORD WITH SS:	ONE OF THE FOLLOW	ING		
i.	Contractual	484,966.00	a. b.	DEDUCTION ADDITIONAL COSTS			b	
j.	TOTAL DIRECT COSTS ————	602,672.00	c. MATCHING d. OTHER RESEARCH (Add / Deduct Option) e. OTHER (See REMARKS)					
k.	INDIRECT COSTS	22,328.00		RD IS BASED ON AN APPLICATION SUBMITTE	ED TO AND AS ADDRO	WED BY THE EE	DEDAL AWARDING AGENCY	
			ON THE ABOVE	TITLED PROJECT AND IS SUBJECT TO THE T	ERMS AND CONDITION	IS INCORPORATE	D EITHER DIRECTLY	
I. TOTAL APPROVED BUDGET 625,000.00		a. The grant program legislation						
		625,000,00	b. c. d.	The grant program regulations. This award notice including terms and condition Federal administrative requirements, cost principal prin	s, if any, noted below un	der REMARKS.	this grant	
m.	Federal Share	625,000.00	In the event th	ere are conflicting or otherwise inconsistent	oolicies applicable to the	ne grant, the abo	ove order of precedence shall	
n.	Non-Federal Share	0.00	prevail. Accep	stance of the grant terms and conditions is act the grant payment system.	knowledged by the gr	antee when fund	s are drawn or otherwise	
RF	MARKS (Other Terms and Conditions Attached -	Yes	No)		- 			
	(Stroit Forms and Conditions Attached		_ ''''					

GRANTS MANAGEMENT OFFICIAL:

Ralph U Robinson, Grants Management Officer 2960 Brandywine Rd Mailstop E01

Atlanta, GA 30341-5509 Phone: 770-488-2441

17.0BJ CI	LASS 41.51	18a. \	ENDOR CODE	18b. EIN		19. D	UNS 878092600	20.	CONG. DIST. 03
F	FY-ACCOUNT NO.		DOCUMENT NO.		ADMINISTRATIVE CODE		AMT ACTION FIN ASST		APPROPRIATION
21. a.	9-9390AVT	b.	19NUE1EH001393	C.	EH	d.	\$0.00	e.	75-19-0947
22. a.	0-9390AVT	b.	19NUE1EH001393	C.	EH	d.	\$625,000.00	e.	75-20-0947
23. a.		b.		C.		d.		e.	

NOTICE OF AWARD (Continuation Sheet)

PAGE 2 of 3		DATE ISSUED 06/01/2020
GRANT NO.	5 NU	E1EH001393-02-00

Direct Assistance

BUDGET CATEGORIES	PREVIOUS AMOUNT (A)	AMOUNT THIS ACTION (B)	TOTAL (A + B)
Personnel	\$0.00	\$0.00	\$0.00
Fringe Benefits	\$0.00	\$0.00	\$0.00
Travel	\$0.00	\$0.00	\$0.00
Equipment	\$0.00	\$0.00	\$0.00
Supplies	\$0.00	\$0.00	\$0.00
Contractual	\$0.00	\$0.00	\$0.00
Construction	\$0.00	\$0.00	\$0.00
Other	\$0.00	\$0.00	\$0.00
Total	\$0.00	\$0.00	\$0.00

NOTICE OF AWARD (Continuation Sheet)

PAGE 3 of 3		DATE ISSUED 06/01/2020	
GRANT NO.	5 NU	E1EH001393-02-00	

Federal Financial Report Cycle						
Reporting Period Start Date Reporting Period End Date Reporting Type Reporting Period Due Date						
09/01/2019	08/31/2020	Annual	11/29/2020			

AWARD ATTACHMENTS

Missouri Department of Health

5 NUE1EH001393-02-00

1. EH19-1902 Yr. 2 T&C EH001393

AWARD INFORMATION

Incorporation: In addition to the federal laws, regulations, policies, and CDC General Terms and Conditions for Non-research awards at

https://www.cdc.gov/grants/federalregulationspolicies/index.html, the Centers for Disease Control and Prevention (CDC) hereby incorporates Notice of Funding Opportunity (NOFO) number EH19-1902, entitled A Comprehensive Public Health Approach to Asthma Control Through Evidence-Based Interventions, and application dated April 24, 2020, as may be amended, which are hereby made a part of this Non-research award, hereinafter referred to as the Notice of Award (NoA).

Approved Funding: Funding in the amount of \$625,000 is approved for the Year 2 budget period, which is September 1, 2020 through August 31, 2021. All future year funding will be based on satisfactory programmatic progress and the availability of funds.

The federal award amount is subject to adjustment based on total allowable costs incurred and/or the value of any third party in-kind contribution when applicable.

Note: Refer to the Payment Information section for Payment Management System (PMS) subaccount information.

Financial Assistance Mechanism: Cooperative Agreement

Substantial Involvement by CDC: This is a cooperative agreement and CDC will have substantial programmatic involvement after the award is made. Substantial involvement is in addition to all post-award monitoring, technical assistance, and performance reviews undertaken in the normal course of stewardship of federal funds.

Supporting recipients to implement cooperative agreement requirements and advance program activities to meet outcomes.

- Providing technical assistance to revise annual work plans and budgets.
- Providing expertise and resources related to scientific subject matter and health care systems.
- -Providing consultation and guidance on enhancing and expanding existing asthma surveillance activities, including the analysis and interpretation of data sets.
- Providing advice on the development, publication, and dissemination of surveillance reports, fact sheets, or other data products.
- Collaborating with recipients to develop and implement strategic and individual evaluation plans and use evaluation findings.
- Providing technical assistance to operationalize and report performance measures.
- Analyzing recipient performance measurement data and evaluation findings to provide suggestions for program improvement.
- Engaging recipients in cross-state evaluations of program activities and outcomes. Establishing and facilitating learning opportunities to increase information sharing among recipients.
- Providing professional development and training opportunities, either in person or through virtual web-based training formats for the purpose of sharing best practices and the latest science on asthma.
- Convening in-person meetings that provide recipients with opportunities to exchange resources, share lessons learned and address common issues.

Technical Review Response Requirement: The reviewer comments on the strengths and weaknesses of the proposal are provided as part of this award and are located in Grant Solutions. A response to the weaknesses in these statements must be uploaded for approval into Grant Solutions as a Note and submitted to the Project Officer noted in the CDC Staff Contacts section of this NoA, no later than 30 days from the budget period start date. Failure to submit the required information by the due date, October 1, 2020, will cause delay in programmatic progress and will adversely affect the future funding of this project.

Expanded Authority: The recipient is permitted the following expanded authority in the administration of the award.

☑ Carryover of unobligated balances from one budget period to a subsequent budget period. Unobligated funds may be used for purposes within the scope of the project as originally approved. Recipients will report use, or intended use, of unobligated funds in Section 12 "Remarks" of the annual Federal Financial Report. If the GMO determines that some or all of the unobligated funds are not necessary to complete the project, the GMO may restrict the recipient's authority to automatically carry over unobligated balances in the future, use the balance to reduce or offset CDC funding for a subsequent budget period, or use a combination of these actions.

<u>Addition alternative</u>: Under this alternative, program income is added to the funds committed to the project/program and is used to further eligible project/program objectives.

Note: The disposition of program income must have written prior approval from the GMO.

FUNDING RESTRICTIONS AND LIMITATIONS

Indirect Costs:

Indirect costs are approved based on the negotiated indirect cost rate agreement dated March 17, 2020, which calculates indirect costs as follows, a Final is approved at a rate of 20.10% of the base, which includes, Direct salaries and wages including all fringe benefits. The effective dates of this indirect cost rate are from July 1, 2020 to June 30, 2021.

REPORTING REQUIREMENTS

Performance Progress and Monitoring: Performance information collection initiated under this grant/cooperative agreement has been approved by the Office of Management and Budget under OMB Number 0920-1132, "Performance Progress and Monitoring Report", Expiration Date 10/31/2022. The components of the PPMR are available for download at: https://www.cdc.gov/grants/alreadyhavegrant/Reporting.html.

Required Disclosures for Federal Awardee Performance and Integrity Information System (FAPIIS): Consistent with 45 CFR 75.113, applicants and recipients must disclose in a timely manner, in writing to the CDC, with a copy to the HHS Office of Inspector General (OIG), all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Subrecipients must disclose, in a timely manner in writing to the prime recipient (pass through entity) and the HHS OIG, all information related to violations of federal criminal law involving fraud, bribery, or gratuity violations potentially affecting the federal award. Disclosures must be sent in writing to the CDC and to the HHS OIG at the following addresses:

CDC, Office of Grants Services Julie Davis, Grants Management Specialist Centers for Disease Control and Prevention 2939 Flowers Rd Atlanta, GA 30341

Email: xxg6@cdc.gov (Include "Mandatory Grant Disclosures" in subject line)

AND

U.S. Department of Health and Human Services
Office of the Inspector General
ATTN: Mandatory Grant Disclosures, Intake Coordinator
330 Independence Avenue, SW
Cohen Building, Room 5527
Washington, DC 20201

Fax: (202)-205-0604 (Include "Mandatory Grant Disclosures" in subject line) or

Email: MandatoryGranteeDisclosures@oig.hhs.gov

Recipients must include this mandatory disclosure requirement in all subawards and contracts under this award.

Failure to make required disclosures can result in any of the remedies described in 45 CFR 75.371. Remedies for noncompliance, including suspension or debarment (See 2 CFR parts 180 and 376, and 31 U.S.C. 3321).

CDC is required to report any termination of a federal award prior to the end of the period of performance due to material failure to comply with the terms and conditions of this award in the OMB-designated integrity and performance system accessible through SAM (currently FAPIIS). (45 CFR 75.372(b)) CDC must also notify the recipient if the federal award is terminated for failure to comply with the federal statutes, regulations, or terms and conditions of the federal award. (45 CFR 75.373(b))

PAYMENT INFORMATION

The HHS Office of the Inspector General (OIG) maintains a toll-free number (1-800-HHS-TIPS [1-800-447-8477]) for receiving information concerning fraud, waste, or abuse under grants and cooperative agreements. Information also may be submitted by e-mail to hhstips@oig.hhs.gov or by mail to Office of the Inspector General, Department of Health and Human Services, Attn: HOTLINE, 330 Independence Ave., SW, Washington DC 20201. Such reports are treated as sensitive material and submitters may decline to give their names if they choose to remain anonymous.

Payment Management System Subaccount: Funds awarded in support of approved activities have been obligated in a subaccount in the PMS, herein identified as the "P Account". Funds must be used in support of approved activities in the NOFO and the approved application.

The grant document number identified on the bottom of Page 1 of the Notice of Award must be

known in order to draw down funds.

PROGRAM OR FUNDING SPECIFIC CLOSEOUT REQUIREMENTS

Final Performance Progress and Evaluation Report: This report should include the information specified in the NOFO and is submitted 90 days following the end of the period of performance via www.grantsolutions.gov. At a minimum, the report will include the following:

- Statement of progress made toward the achievement of originally stated aims.
- Description of results (positive or negative) considered significant.
- List of publications resulting from the project, with plans, if any, for further publication.

Additional guidance may be provided by the GMS and found at: https://www.cdc.gov/grants/alreadyhavegrant/Reporting.html

Information collection initiated under this grant/cooperative agreement has been approved by

CDC Staff Contacts

Grants Management Specialist: The GMS is the federal staff member responsible for the day-to-day management of grants and cooperative agreements. The GMS is the primary contact of recipients for business and administrative matters pertinent to grant awards.

GMS Contact:

Julie Davis, Grants Management Specialist Centers for Disease Control and Prevention Office of Financial Resources 2939 Flowers Rd. Atlanta, GA 30341

Telephone: 770-488-2936 Email: xxg6@cdc.gov

Program/Project Officer: The PO is the federal official responsible for monitoring the programmatic, scientific, and/or technical aspects of grants and cooperative agreements, as well as contributing to the effort of the award under cooperative agreements.

Programmatic Contact:

Daniel J. Burrows
Centers for Disease Control and Prevention
NCEH Air Pollution and Respiratory Health Branch
770-488-3722
dburrows@cdc.gov

Grants Management Officer: The GMO is the federal official responsible for the business and other non-programmatic aspects of grant awards. The GMO is the only official authorized to obligate federal funds and is responsible for signing the NoA, including revisions to the NoA that change the terms and conditions. The GMO serves as the counterpart to the business officer of the recipient organization.

GMO Contact:

Ralph U Robinson

Centers for Disease Control and Prevention Office of Financial Resources(OFR) 2939 Flowers Rd.

Atlanta, GA 30341 Phone: 770-488-2441 Email: inp2@cdc.gov